Q1 2020

Filed May 8, 2020 · 10-Q · 38 days after period end · 0000886163-20-000061

Q1 2020 · 10-Q

Revenue

$33.16M

−23.7% vs Q1 2019

Net Income

-$24.13M

N/M vs Q1 2019

EPS Diluted

-$1.46

N/M vs Q1 2019

Operating Income$3,788,000−99.5%

Operating Cash Flow

Same quarter

Metric	Q1 2020	Q1 2019	Q1 2018	Q1 2017
Revenue	$33.16M	$43.48M	$56.16M	$56.16M
Net Income	-$24.13M	$666.34M	$45.28M	$45.28M
EPS Diluted	-$1.46	$31.32	$1.83	$1.83

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR